Literature DB >> 512635

Glaucescin, a bacteriocin-like substance from Streptomyces glaucescens.

W Schurter, M Kissling-Abderhalden, T Leisinger.   

Abstract

Streptomyces glaucescens ETH 22794 produced a variety of antibiotic substances. Besides low molecular weight antibiotics like hydroxystreptomycin and the tetracenomycins, this strain excreted glaucescin, a high molecular weight product with bacteriocin-like properties. In plate tests the antagonism of glaucescin against Streptomyces canadiensis was masked by the large inhibition zone caused by the tetracenomycins. Glaucescin activity was revealed when a tetracenomycin-resistant mutant of S. canadiensis NRRL 3155 was used as an indicator. Glaucesin was produced on complex and minimal solid and liquid media. It was not inducible by mitomycin C. The killing activity of glaucescin was thermolabile and resistant to DNAase, RNAase, various proteinases, and lipase. Its apparent molecular weight was estimated as 196000 by gel filtration and glycerol gradient centrifugation. Glaucescin preferentially killed outgrowing spores of S. canadiensis. Resting spores and mycelium were considerably less sensitive to the inhibitor, and adsorption of glaucescin by S. canadiensis paralleled sensitivity. The activity spectrum of the bacteriocin was restricted to spore-forming Actinomycetales. Non spore-forming nocardiae and a variety of Gram-positive and Gram-negative bacteria were resistant to glaucescin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 512635     DOI: 10.1099/00221287-113-2-243

Source DB:  PubMed          Journal:  J Gen Microbiol        ISSN: 0022-1287


  2 in total

1.  Production of Antimicrobial and Bacteriocin-Like Substances by Rhizobium trifolii.

Authors:  M V Joseph; J D Desai; A J Desai
Journal:  Appl Environ Microbiol       Date:  1983-02       Impact factor: 4.792

2.  Isolation of tetracenomycin C-nonproducing Streptomyces glaucescens mutants.

Authors:  H Motamedi; E Wendt-Pienkowski; C R Hutchinson
Journal:  J Bacteriol       Date:  1986-08       Impact factor: 3.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.